Guidelines and literature

• 2022

  Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.

  HERRMANN, K. et al., Joint EANM, SNMMI and IAEA Enabling Guide: How to Set up a Theranostics Centre, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Springer Science and Business Media LLC (2022) pp. 2300–2309

• 2020

  Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study

  Strosberg, J. K., P. L.: Hendifar, A.: Yao, J.: Bushnell, D.: Kulke, M. H.: Baum, R. P.: Caplin, M.: Ruszniewski, P.: Delpassand, E.: Hobday, T.: Verslype, C.: Benson, A.: Srirajaskanthan, R.: Pavel, M.: Mora, J.: Berlin, J.: Grande, E.: Reed, N.: Seregni, E.: Paganelli, G.: Severi, S.: Morse, M.: Metz, D. C.: Ansquer, C.: Courbon, F.: Al-Nahhas, A.: Baudin, E.: Giammarile, F.: Ta├?eb, D.: Mittra, E.: Wolin, E.: O'Dorisio, T. M.: Lebtahi, R.: Deroose, C. M.: Grana, C. M.: Bodei, L.: ├?berg, K.: Polack, B. D.: He, B.: Mariani, M. F.: Gericke, G.: Santoro, P.: Erion, J. L.: Ravasi, L.: Krenning, E. (2020). Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-020-04709-x

• 2020

  Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

  Ahmadzadehfar, H. R., K.: Baum, R. P.: Seifert, R.: Kessel, K.: Bogemann, M.: Kulkarni, H. R.: Zhang, J.: Gerke, C.: Fimmers, R.: Kratochwil, C.: Rathke, H.: Ilhan, H.: Maffey-Steffan, J.: Sathekge, M.: Kabasakal, L.: Garcia-Perez, F. O.: Kairemo, K.: Maharaj, M.: Paez, D.: Virgolini, I. (2020). Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/32383093. doi:10.1007/s00259-020-04797-9

• 2019

  Positive effect of Actinium 225-PSMA treatment on ECOG performance status: A case report on a patient with castration resistant stage IV prostate carcinoma

  Novruzov, F. A., Jamil A: Allahverdiyeva, Zeyn?b: Mehdi, Elnur: Giammarile, Francesco. (2019). Positive effect of Actinium 225-PSMA treatment on ECOG performance status: A case report on a patient with castration resistant stage IV prostate carcinoma. Revista espanola de medicina nuclear e imagen molecular. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30665750.

• 2018

  Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse

  Delgado Bolton, R. C. G., F. (2018). Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse. Eur J Nucl Med Mol Imaging, 45(5), 822-823. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29333576: https://link.springer.com/content/pdf/10.1007%2Fs00259-017-3913-z.pdf. doi:10.1007/s00259-017-3913-z

• 2018

  EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides

  Handkiewicz-Junak, D. P., T. D.: Bodei, L.: Aktolun, C.: Ezziddin, S.: Giammarile, F.: Delgado-Bolton, R. C.: Gabriel, M. (2018). EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging, 45(5), 846-859. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29453701: https://link.springer.com/content/pdf/10.1007%2Fs00259-018-3947-x.pdf: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978928/pdf/259_2018_Articl.... doi:10.1007/s00259-018-3947-x

• 2012

  Timing and optimized acquisition parameters for the whole-body imaging of (1)(7)(7)Lu-EDTMP toward performing bone pain palliation treatment

  Liu, C. B., J. R.: Liu, X.: Li, H.: Xiang, X.: Luo, Z.: Wang, Y.: Kuai, D.: Zhang, G.: Zaknun, J. J. (2012). Timing and optimized acquisition parameters for the whole-body imaging of (1)(7)(7)Lu-EDTMP toward performing bone pain palliation treatment. Nucl Med Commun, 33(1), 90-96. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22001721. doi:10.1097/MNM.0b013e32834d3c13

Nuclear Oncology

• 2020

  Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis

  WARD, Z.J., et al., Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis, The Lancet Oncology 21 8 (2020) 1077 - 1088.

PET, Oncology, Therapy

• 2021

  Neuroblastomas Current Diagnostic and Therapeutic Approaches in Nuclear Endocrinology

  SHULKIN, B.L., et al., Neuroblastomas Current Diagnostic and Therapeutic Approaches in Nuclear Endocrinology, Cambridge Scholars Publishing: Current Diagnostic and Therapeutic Approaches in Nuclear Endocrinology, (2021).

Radionuclide Therapy

• 2019

  Efficacy of 177Lu Peptide Receptor?Radionuclide?Therapy?for the Treatment of Neuroendocrine Tumors: A Meta-analysis.

  Saravana-Bawan, B., Bajwa, A., Paterson, J., McEwan, A. J. B., & McMullen, T. P. W. (2019). Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis. Clin Nucl Med, 44(9), 719-727. doi:10.1097/rlu.0000000000002646

• 2019

  NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE (2019)

  Hope, T. A., Abbott, A., Colucci, K., Bushnell, D. L., Gardner, L., Graham, W. S., . . . Strosberg, J. R. (2019). NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. J Nucl Med, 60(7), 937-943. doi:10.2967/jnumed.118.230607

• 2019

  Radioiodine remnant ablation in papillary thyroid microcarcinoma: a meta-analysis.

  Yang, T., Zheng, S. Y., Jiao, J., Zou, Q., & Zhang, Y. (2019). Radioiodine remnant ablation in papillary thyroid microcarcinoma: a meta-analysis. Nucl Med Commun, 40(7), 711-719. doi:10.1097/mnm.0000000000001018

• 2019

  Radioligand?Therapy?With?177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

  Yadav, M. P., Ballal, S., Sahoo, R. K., Dwivedi, S. N., & Bal, C. (2019). Radioligand Therapy With (177)Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol, 213(2), 275-285. doi:10.2214/ajr.18.20845

• 2018

  EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer?(2018)

  Poeppel, T. D., Handkiewicz-Junak, D., Andreeff, M., Becherer, A., Bockisch, A., Fricke, E., . . . Gabriel, M. (2018). EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 45(5), 824-845. Retrieved from https://doi.org/10.1007/s00259-017-3900-4. doi:10.1007/s00259-017-3900-4

• 2018

  Intra-arterial?therapies?for unresectable and chemorefractory colorectal cancer liver metastases: a?systematic review and meta-analysis.

  Levy, J., Zuckerman, J., Garfinkle, R., Acuna, S. A., Touchette, J., Vanounou, T., & Pelletier, J. S. (2018). Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a?systematic review and meta-analysis. HPB (Oxford), 20(10), 905-915. doi:10.1016/j.hpb.2018.04.001

• 2016

  Radioiodine?therapy?versus antithyroid medications for Graves' disease.

  Ma, C., Xie, J., Wang, H., Li, J., & Chen, S. (2016). Radioiodine therapy versus antithyroid medications for Graves' disease. Cochrane Database Syst Rev, 2, Cd010094. doi:10.1002/14651858.CD010094.pub2

• 2016

  Relation between?therapy?options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.

  Li, H. X., Xiang, N., Hu, W. K., & Jiao, X. L. (2016). Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest, 39(11), 1225-1233. doi:10.1007/s40618-016-0484-y

• 2016

  Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.

  Rognoni, C., Ciani, O., Sommariva, S., Facciorusso, A., Tarricone, R., Bhoori, S., & Mazzaferro, V. (2016). Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget, 7(44), 72343-72355. doi:10.18632/oncotarget.11644

• 2015

  Recombinant human thyrotropin before (131)I?therapy?in patients with nodular goitre: a meta-analysis of randomized controlled trials.

  Lee, Y. Y., Tam, K. W., Lin, Y. M., Leu, W. J., Chang, J. C., Hsiao, C. L., . . . Hsieh, A. T. (2015). Recombinant human thyrotropin before (131)I therapy in patients with nodular goitre: a meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf), 83(5), 702-710. doi:10.1111/cen.12654

• 2015

  Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.

  Al-Adra, D. P., Gill, R. S., Axford, S. J., Shi, X., Kneteman, N., & Liau, S. S. (2015). Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol, 41(1), 120-127. doi:10.1016/j.ejso.2014.09.007

• 2014

  (131)I-MIBG?therapy?for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis.

  van Hulsteijn, L. T., Niemeijer, N. D., Dekkers, O. M., & Corssmit, E. P. (2014). (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf), 80(4), 487-501. doi:10.1111/cen.12341

• 2012

  SNMMI Procedure Standard for?Therapy of Thyroid Disease with?131I (Sodium Iodide) 3.0 (2012)

  Silberstein, E. B., Alavi, A., Balon, H. R., Clarke, S. E., Divgi, C., Gelfand, M. J., . . . Waxman, A. D. (2012). The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med, 53(10), 1633-1651. doi:10.2967/jnumed.112.105148

• 2012

  Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

  Schlumberger, M., Catargi, B., Borget, I., Deandreis, D., Zerdoud, S., Bridji, B., . . . Benhamou, E. (2012). Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med, 366(18), 1663-1673. doi:10.1056/NEJMoa1108586

• 2012

  Targeted "bone-seeking" radiopharmaceuticals for palliative treatment of bone metastases: a systematic review and meta-analysis.

  D'Angelo, G., Sciuto, R., Salvatori, M., Sperduti, I., Mantini, G., Maini, C. L., & Mariani, G. (2012). Targeted "bone-seeking" radiopharmaceuticals for palliative treatment of bone metastases: a systematic review and meta-analysis. Q J Nucl Med Mol Imaging, 56(6), 538-543.

• 2011

  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds?(2011)

  Giammarile, F., Bodei, L., Chiesa, C., Flux, G., Forrer, F., Kraeber-Bodere, F., . . . Dosimetry, C. (2011). EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. European Journal of Nuclear Medicine and Molecular Imaging, 38(7), 1393. Retrieved from https://doi.org/10.1007/s00259-011-1812-2. doi:10.1007/s00259-011-1812-2

• 2010

  EANM procedure guidelines for therapy of benign thyroid disease?(2010)

  Stokkel, M. P. M., Handkiewicz Junak, D., Lassmann, M., Dietlein, M., & Luster, M. (2010). EANM procedure guidelines for therapy of benign thyroid disease. European Journal of Nuclear Medicine and Molecular Imaging, 37(11), 2218-2228. Retrieved from https://doi.org/10.1007/s00259-010-1536-8. doi:10.1007/s00259-010-1536-8

• 2008

  EANM procedure guideline for treatment of refractory metastatic bone pain?(2008)

  Bodei, L., Lam, M., Chiesa, C., Flux, G., Brans, B., Chiti, A., & Giammarile, F. (2008). EANM procedure guideline for treatment of refractory metastatic bone pain. European Journal of Nuclear Medicine and Molecular Imaging, 35(10), 1934. Retrieved from https://doi.org/10.1007/s00259-008-0841-y. doi:10.1007/s00259-008-0841-y

• 2008

  EANM procedure guidelines for?131I-meta-iodobenzylguanidine (131I-mIBG) therapy?(2008)

  Giammarile, F., Chiti, A., Lassmann, M., Brans, B., & Flux, G. (2008). EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. European Journal of Nuclear Medicine and Molecular Imaging, 35(5), 1039-1047. Retrieved from https://doi.org/10.1007/s00259-008-0715-3. doi:10.1007/s00259-008-0715-3

• 2008

  Guidelines for radioiodine therapy of differentiated thyroid cancer?(2008)

  Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., . . . Bombardieri, E. (2008). Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 35(10), 1941. Retrieved from https://doi.org/10.1007/s00259-008-0883-1. doi:10.1007/s00259-008-0883-1

• 2007

  EANM procedure guideline for?32P phosphate treatment of myeloproliferative diseases?(2007)

  Tennvall, J., & Brans, B. (2007). EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases. European Journal of Nuclear Medicine and Molecular Imaging, 34(8), 1324-1327. Retrieved from https://doi.org/10.1007/s00259-007-0407-4. doi:10.1007/s00259-007-0407-4

• 2006

  EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)?(2006)

  Tennvall, J., Fischer, M., Bischof Delaloye, A., Bombardieri, E., Bodei, L., Giammarile, F., . . . Brans, B. (2007). EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging, 34(4), 616-622. doi:10.1007/s00259-007-0372-y

• 2003

  SNMMI Procedure Standard for?Palliative Treatment for Painful Bone Metastases 3.0 (2003)

  Paszkowski, A. L., Hewitt, D. J., & Taylor, A., Jr. (1999). Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Clin Nucl Med, 24(11), 852-854. doi:10.1097/00003072-199911000-00006

• 2002

  EANM Procedure Guidelines for Radiosynovectomy?(2002)

  Clunie, G., & Fischer, M. (2003). EANM procedure guidelines for radiosynovectomy. Eur J Nucl Med Mol Imaging, 30(3), Bp12-16. doi:10.1007/s00259-002-1058-0

• 2002

  Guidelines for?131I – ethiodised oil [Lipiodol] Therapy?(2002)

  Guidelines for 131I-ethiodised oil (Lipiodol) therapy. (2003). Eur J Nucl Med Mol Imaging, 30(3), Bp20-22. doi:10.1007/s00259-002-1060-6

Therapy

• 2021

  The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [(177)Lu]Lu-PSMA-617: a WARMTH multicentre study

  AHMADZADEHFAR, H., et al., The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [(177)Lu]Lu-PSMA-617: a WARMTH multicentre study, Eur J Nucl Med Mol Imaging 48 12 (2021) 4067-4076.

• 2021

  Pain Palliation of Bone Metastases: Production, Quality control and Dosimetry of Radiopharmaceuticals

  KUDO, T., et al., Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia: The IAEA INCAPS-COVID Study, JACC ASIA 1 2 (2021) 187-199.

• 2020

  Selective internal radiation therapy of hepatic tumors: Morphologic and functional imaging for voxel-based computer-aided dosimetry

  SKANJETI, A., et al., Selective internal radiation therapy of hepatic tumors: Morphologic and functional imaging for voxel-based computer-aided dosimetry, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 132 (2020) 110865.